P1.01-053 Italian Nivolumab Expanded Access Programme (EAP): Data from Patients with Advanced Non-Squamous NSCLC and Brain Metastases
Lucio Crinò(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Angelo Delmonte(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Antonio Santo(Casa di Cura Villa Garda), L. Ciuffreda(Azienda Ospedaliero Universitaria San Giovanni Battista), Francesco Grossi(University of Insubria), M.G. Sarobba(Cisco Systems (France)), Anna Illiano(University of Naples Federico II), Gianmauro Numico(Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo), Paola Ulivi(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Giuseppe Tonini(Campus Bio Medico University Hospital), Elisa Minenza, Antonio Frassoldati(Italian Oncology Group of Clinical Research), Riccardo Samaritani(Presidio Ospedaliero), Marco Bregni(Ospedale San Giuseppe), Francovito Piantedosi(Ospedale Monaldi), Paolo Bidoli(Fondazione IRCCS Istituto Nazionale dei Tumori), Enrico Cortesi(Sapienza University of Rome), Marina Chiara Garassino(University of Chicago), Federico Cappuzzo(Ospedale di Livorno), G. Pinotti(Ospedale di Circolo e Fondazione Macchi), Filippo de Marinis(Carlo Forlanini Hospital)
Cited by 8
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k